Global Brain backs Japan's laxative-free cancer screening startup BMS
What's the deal? Global BrainDealroom has a profile for this one. Try Dealroom → has made an additional investment in Boston Medical SciencesDealroom has a profile for this one. Try Dealroom → (BMS), a Tokyo startup building AI technology for CT colonography that aims to enable laxative-free colorectal cancer screening. The firm acted as co-lead through five funds, including its Flagship Fund IX, TOHO Ventures, and the FUKOKU -THE MUTUAL for Next 100 Fund.
What's the endgame? BMS is developing a system called AIM4CRC that pairs a virtual bowel-cleansing AI — which removes residual matter from CT scan images — with an AI that helps clinicians detect polyps. The goal is a full colon examination without the laxative preparation that deters many people from screening.
Why now? The company has hit regulatory milestones in the US market. In May 2026, AIM4CRC won Breakthrough Device designation from the Food and Drug Administration; in June 2026, it was selected for the agency's Total Product Life Cycle Advisory Program.
BMS runs collaborative research with the 3D Imaging Research group at Harvard Medical School and Massachusetts General Hospital, plus Japan's National Cancer Center Hospital. In June 2026 it launched a joint project with the Tokushukai Group on AI-assisted CT colonoscopy.
Global Brain cited the startup's management team of physicians, researchers, and engineers, its proprietary AI, and its regulatory strategy across Japan and the US. It said it will support BMS in moving the technology toward clinical use in both markets.
What could go wrong? AIM4CRC remains an investigational device, not approved or cleared in Japan or the US. Breakthrough designation is not marketing authorisation, and the product must still prove reliable polyp detection and clear regulatory value. CT colonography also stays an alternative to colonoscopy, since positive findings may require follow-up and CT involves radiation.
The signal: Colorectal cancer ranks among the most common cancers and a leading cause of cancer deaths worldwide, with screening avoidance a known barrier. Backing from a co-lead syndicate — alongside earlier state support from Japan's NEDO, which committed US$6.09M for fiscal 2025–26 work — shows investors betting that a less burdensome test could widen screening uptake, if it clears the clinical and regulatory bar.
Read more: globalbrains.com
Image credit: joncallas
